Repatha
Biological
Amgen Inc.
Total Payments
$315.0M
Transactions
521,048
Doctors
86,811
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $14.9M | 77,153 | 28,257 |
| 2023 | $20.5M | 81,622 | 29,261 |
| 2022 | $16.4M | 77,768 | 23,640 |
| 2021 | $41.6M | 61,422 | 18,441 |
| 2020 | $40.4M | 28,772 | 10,198 |
| 2019 | $53.8M | 49,237 | 15,626 |
| 2018 | $55.6M | 99,895 | 34,143 |
| 2017 | $71.9M | 45,179 | 18,098 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $264.9M | 9,998 | 84.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $30.3M | 16,861 | 9.6% |
| Food and Beverage | $12.5M | 479,523 | 4.0% |
| Travel and Lodging | $3.6M | 13,004 | 1.1% |
| Consulting Fee | $3.2M | 1,057 | 1.0% |
| Space rental or facility fees (teaching hospital only) | $523,920 | 298 | 0.2% |
| Education | $20,130 | 307 | 0.0% |
Payments by Type
Research
$264.9M
9,998 transactions
General
$50.1M
511,050 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| FOURIER OLE (Ph 4) | Amgen Inc. | $99.1M | 5 |
| 20170625_VESALIUS - CV | Amgen Inc. | $20.7M | 3 |
| FOURIER OLE (Ph 4) | Amgen Inc. | $17.1M | 2 |
| 20160250-FOURIER OLE (Ph 4) | Amgen Inc. | $14.1M | 1 |
| 20170625-VESALIUS - CV | Amgen Inc. | $12.3M | 0 |
| GOULD | Amgen Inc. | $10.6M | 13 |
| VESALIUS - CV | Amgen Inc. | $9.3M | 1 |
| VESALIUS-CV | Amgen Inc. | $6.7M | 1 |
| Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9i (cvMOBIUS) | Amgen Inc. | $5.0M | 0 |
| Ph3b Evolocumab in HIV Patients | Amgen Inc. | $4.9M | 1 |
| AMG 145-A single dose relative bioavailability study | Amgen Inc. | $3.7M | 0 |
| Collect CV events in RW and establish effectiveness of PCSK9i | Amgen Inc. | $3.7M | 0 |
| (GOULD): a Registry of High Cardiovascular Risk Subjects in the United States | Amgen Inc. | $3.2M | 7 |
| 20130295-FOURIER OLE (Ph 4) | Amgen Inc. | $3.2M | 0 |
| Ph3b Diabetes Patients | Amgen Inc. | $2.7M | 4 |
| P4 - Registry EHR Data Extract With DCRI | Amgen Inc. | $2.1M | 0 |
| Evolocumab in Patients with ST Elevation and non-ST-elevation Myocardial Infarction: A Double-blind, Prospective, Randomized Placebo-Controlled Study | Amgen Inc. | $2.0M | 0 |
| Effect of Evolocumab on Coronary Plaque Characteristics: a Multimodality Imaging Study | Amgen Inc. | $2.0M | 0 |
| UAB Cardiovascular Collaboration 2018 (Cardiovascular Disease, Prevention, Treatment and Outcomes) | Amgen Inc. | $1.8M | 0 |
| OSLER2 Ph3 OLE | Amgen Inc. | $1.7M | 3 |
Top Doctors Receiving Payments for Repatha — Page 3473
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , CRNP | Family | Hueytown, AL | $2.46 | 1 |
| , PA-C | Physician Assistant | Apex, NC | $2.38 | 1 |
| , M.D | Family Medicine | West Monroe, LA | $2.31 | 1 |
| , M.D | Internal Medicine | Pasadena, MD | $2.25 | 1 |
| , MD | Family Medicine | Redding, CA | $2.07 | 1 |
| Jocelyn Carnicle | Student in an Organized Health Care Education/Training Program | New Orleans, LA | $1.43 | 1 |
| , M.D | Interventional Cardiology | Bryan, OH | $1.29 | 1 |
| , MD | Internal Medicine | Cleveland, TN | $1.18 | 1 |
| , DNP | Family | Birmingham, AL | $1.09 | 1 |
| , CRNP | Nurse Practitioner | Birmingham, AL | $0.99 | 1 |
| Peter Luea | — | Lansing, MI | $0.69 | 1 |
| , MD | Internal Medicine | Franklin, IN | $0.48 | 1 |
Ad
Manufacturing Companies
- Amgen Inc. $315.0M
Product Information
- Type Biological
- Total Payments $315.0M
- Total Doctors 86,811
- Transactions 521,048
About Repatha
Repatha is a biological associated with $315.0M in payments to 86,811 healthcare providers, recorded across 521,048 transactions in the CMS Open Payments database. The primary manufacturer is Amgen Inc..
Payment data is available from 2017 to 2024. In 2024, $14.9M was paid across 77,153 transactions to 28,257 doctors.
The most common payment nature for Repatha is "Unspecified" ($264.9M, 84.1% of total).
Repatha is associated with 20 research studies, including "FOURIER OLE (Ph 4)" ($99.1M).